IgG Binding Protein LT in Support of a Healthy Gut on the Go

Summary

PS52 is a randomized, double-blind, placebo-controlled, fully decentralized study sponsored by Bactolife A/S and conducted by People Science, Inc. It evaluates whether IgG Binding Protein LT (BP-LT), supports gut health in healthy US adults aged 18-70 travelling 7-21 days to Africa, Asia or Latin America/Caribbean countries. Participants are randomized 1:1 to BP-LT (one 75 mg capsule twice daily with food, 150 mg/day) or a matching placebo for the length of their trip. The primary endpoint is the change in GSRS total score from Baseline to End-of-Study versus placebo.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Gut Health
• Gastrointestinal Symptoms
• Safety in Healthy Adults

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

18 to 70 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Bactolife A/S

Last updated on ClinicalTrials.gov

October 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites